1） Moore AR, Rosenberg SC, McCormick F, et al : RAS-targeted therapies : is the undruggable drugged ? Nat Rev Drug
Discov 19 : 533-552, 2020
2） Hong DS, Fakih MG, Strickler JH, et al : KRAS
G12C
Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J
Med 383 : 1207-1217, 2020
3） Jänne PA, Riely GJ, Gadgeel SM, et al : Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.
N Engl J Med 387 : 120-131, 2022
4） Kitazawa M, Hida S, Fujii C, et al : ASC Induces Apoptosis via Activation of Caspase-9 by Enhancing Gap JunctionMediated Intercellular Communication. PLoS One 12 : e0169340, 2017
5） Koyama M, Kitazawa M, Nakamura S, et al : Low-dose trametinib and Bcl-xL antagonist have a specific antitumor
effect in KRAS-mutated colorectal cancer cells. Int J Oncol 57 : 1179-1191, 2020
6） Kitazawa M, Miyagawa Y, Koyama M, et al : Drug sensitivity profile of minor KRAS mutations in colorectal cancer
using mix culture assay : The effect of AMG-510, a novel KRAS G12C selective inhibitor, on colon cancer cells is
markedly enhanced by the combined inhibition of MEK and BCL-XL. Mol Clin Oncol 15 : 148, 2021
7）
Hondo N, Kitazawa M, Koyama M, et al : MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance
signals and enhance its antitumor effect in colorectal cancer cells. Cancer Lett 567 : 216264, 2023
No. 6, 2023
391
北沢・小山・中村ら
8） Parikh K, Banna G, Liu SV, et al : Drugging KRAS : current perspectives and state-of-art review. J Hematol Onco
15 : 152, 2023
9）
Ostrem JM, Peters U, Sos ML, et al : K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions.
Nature 503 : 548-551, 2013
10） Canon J, Rex K, Saiki AY, et al : The clinical KRAS（ G12C ）inhibitor AMG 510 drives anti-tumour immunity.
Nature 575 : 217-223, 2019
11） Hallin J, Engstrom LD, Hargis L, et al : The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic
Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients Cancer Discov 10 : 54-71, 2020
12） Troiani T, Napolitano S, Martini G, et al : Maintenance Treatment with Cetuximab and BAY86-9766 Increases
Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. Clin Cancer Res
21 : 4153-4164, 2015
13） Engelman JA, Chen L, Tan X, et al : Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA
H1047R murine lung cancers. Nat Med 14 : 1351-1356, 2008
14）
Corcoran RB, Cheng KA, Hata AN, et al : Synthetic lethal interaction of combined BCL-XL and MEK inhibition
promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 23 : 121-128, 2013
15） Russo M, Di Nicolantonio F, Bardelli A : Climbing RAS, the everest of oncogenes. Cancer Discov 4 : 19-21, 2014
16）
Ascierto PA, Dummer R, Gogas HJ, et al : Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination
Treatment of BRAF-Mutant Melanoma : Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. J Clin
Oncol : JCO2202322, 2023
17） Hyman DM, Puzanov I, Subbiah V, et al : Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
N Engl J Med 373 : 726-736, 2015
18）
Riely GJ, Smit EF, Ahn MJ, et al : Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With
BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol 41 : 3700-3711, 2023
19） Van Cutsem E, Taieb J, Yaeger R, et al : ANCHOR CRC : Results From a Single-Arm, Phase II Study of Encorafenib
Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer. J Clin
Oncol 41 : 2628-2637, 2023
20） Amodio V, Yaeger R, Arcella P, et al : EGFR Blockade Reverts Resistance to KRAS G12C Inhibition in Colorectal
Cancer. Cancer Discov 10 : 1129-1139, 2020
21）
Yaeger R, Weiss J, Pelster MS, et al : Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated
KRAS G12C. N Engl J Med 388 : 44-54, 2023
22） Ryan MB, Fece de la Cruz F, Phat S, et al : Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance
to KRAS G12C Inhibition. Clin Cancer Res 26 : 1633-1643, 2020
23） Wang X, Allen S, Blake JF, et al : Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D
Inhibitor. J Med Chem 65 : 3123-3133, 2022
24）
Sakamoto K, Masutani T, Hirokawa T, et al : Generation of KS-58 as the first K-Ras (G12D)-inhibitory peptide
presenting anti-cancer activity in vivo. Sci Rep 10 : 21671, 2020
25） Sakamoto K, Qi Y, Miyako E : Nanoformulation of the K-Ras (G12D)-inhibitory peptide KS-58 suppresses colorectal
and pancreatic cancer-derived tumors. Sci Rep 13 : 518, 2023
26） Feng J, Hu Z, Xia X, et al : Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor
efficacy in KRASG12D-mutated colorectal cancer. Oncogene 42 : 1620-1633, 2023
27） Hofmann MH, Gmachl M, Ramharter J, et al : BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is
Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Cancer Discov 11 : 142-157, 2021
（Ｒ 5. 8. 25 受稿） 392
信州医誌 Vol. 71
...
論文の公開元へ
